Which medications are being investigated as possible treatments for low HDL cholesterol (hypoalphalipoproteinemia)?

Updated: May 21, 2021
  • Author: Vibhuti N Singh, MD, MPH, FACC, FSCAI; Chief Editor: George T Griffing, MD  more...
  • Print

Several novel approaches to increasing HDL cholesterol that have been under investigation include the following:

  • The aforementioned partial CETP inhibitor, torcetrapib, may increase HDL by as much as 46%.

  • The glitazones, which are PPAR (peroxisome proliferator-activated receptor) agonists, act by lowering free fatty acid (FFA) and TG levels and by raising HDL. Rosiglitazone appears to increase the size of small LDL particles.

  • Recombinant apo A-1 Milano mimics the activity of nascent HDL and has shown promise in early trials in patients with acute coronary syndromes.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!